Sri Rezeki Hadinegoro.

Sri Rezeki Hadinegoro, M.D., Ph.D.D., Maria Rosario Capeding, M.D., Carmen Deseda, M.D., Tawee Chotpitayasunondh, M.D., Reynaldo Dietze, M.D., H.I. Hj Muhammad Ismail, M.B., B.S., Humberto Reynales, M.D., Ph.D., Kriengsak Limkittikul, M.D., Doris Maribel Rivera-Medina, M.D., Huu Ngoc Tran, M.D., Ph.D., Alain Bouckenooghe, M.D., Danaya Chansinghakul, M.D.D., Karen Fanouillere, M.Sc., M.P.H., Remi Forrat, M.D., Carina Frago, M.D., Sophia Gailhardou, Pharm.D., Nicholas Jackson, Ph.D., Fernando Noriega, M.D., Eric Plennevaux, Ph.D., T. Anh Wartel, M.D., Betzana Zambrano, M.D., and Melanie Saville, M.B., B.S.1,2 The vaccine was administered in 3 doses: at baseline, at six months, and at 12 a few months.Rader, M.D., James A. De Lemos, M.D., and Philip W. Shaul, M.D.: HDL Cholesterol Efflux Incident and Capability Cardiovascular Events A low level of high-density lipoprotein cholesterol is a significant independent risk aspect for atherosclerotic cardiovascular disease.1 However, in randomized, controlled trials, high-dosage niacin or inhibitors of cholesteryl ester transfer proteins didn’t improve cardiovascular outcomes despite significantly increasing the HDL cholesterol level.2-5 Furthermore, genetic variants associated with HDL cholesterol levels aren’t associated with cardiovascular disease often. 6 These observations claim that HDL cholesterol might not be causally associated with coronary disease, plus they highlight the potential limitations of using the HDL cholesterol level to assess risk or responses to therapies targeted at HDL cholesterol.